U.S. FDA Pinpoints Culprit In Bad Heparin
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA has evaluated data that provides "a very solid mechanistic link" between patients who have received bolus dosing of contaminated heparin and observed adverse reactions, according to Center for Drug Evaluation and Research Director Janet Woodcock